On Wednesday, Vir Biotechnology, Inc. VIR introduced preliminary Section 1 knowledge from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a wide range of HER2-expressing stable tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate most cancers (mCRPC).
Knowledge present encouraging preliminary security and efficacy profiles with no dose-limiting cytokine launch syndrome, most tolerated dose not but reached as dose escalation continues, and early scientific response alerts noticed in closely pretreated members.
On Thursday, Morgan Stanley upgraded Vir Biotechnology, noting that “preliminary knowledge present early platform de-risking and see potential for exercise to enhance as dose escalation continues.”
Early efficacy knowledge point out that fifty% (10/20) of members receiving VIR-5818 doses ≥400 µg/kg skilled dose-dependent tumor shrinkage throughout a number of HER2-positive tumor varieties.
Analyst Michael E Ulz, citing administration, writes that the response price of ~33% is sufficient to speed up growth.
The analyst upgrades Vir Biotechnology from Equal-weight to Obese with a value goal of $20, up from $10.
The Morgan Stanley analyst is optimistic concerning the early outcomes, exhibiting promising exercise and manageable security in each applications. They’re awaiting knowledge from larger doses to substantiate security and see stronger effectiveness.
Analyst Michael E Ulz writes that encouraging early outcomes de-risks the TCE platform.
The mannequin now contains VIR-5500 income projections for prostate most cancers and barely decrease working bills primarily based on revised money steerage. Nevertheless, the analyst has eliminated Hepatitis B revenues.
Worth Motion: VIR inventory is up 0.24% at $12.51 eventually verify Friday.
Learn Subsequent:
Photograph through Shutterstock.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
